Clinical Trial Update: Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating pembrolizumab in combination with nab-paclitaxel for HER-2 negative metastatic breast cancer; results have been posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: NYU Langone Health | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-03-06